NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Sight Diagnostics

Sight Diagnostics

Private
Tel AvivHealthcare & Life Scienceshttps://sightdx.com

Last Round

Series D

Aug 5, 2020

Total Funding Raised

$120.6M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Sight Diagnostics is a health tech company that develops automated microscopy devices and AI-powered platforms for rapid, lab-grade blood testing.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Computer Vision, Medical AI

Business Model

B2B

Customer Profile

Hardware Sales, Hardware + Subscription

AI Layer

Application

Keywords

point-of-care diagnosticscomplete blood countCBCblood analyzercomputer visionmedical AIfinger-prick blood testhematology analyzerdigital hematologyrazor-and-blades modelclinical diagnosticslab-on-a-chipmedtechhealthtech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Sight Diagnostics Comps

Public and private peers based on sector, stage, and business model.

Sight Diagnostics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Sight Diagnostics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DAug 5, 2020
Series CFeb 14, 2019
Series BAug 1, 2016
Series AApr 8, 2014

Key People

Founding team and executive leadership

Nitsan Maayan-Rabinowich

CEO, Board Member

Executive Team

Ben Leshem

CTO, Sight Diagnostics

Executive Team

Yoav Shmaya

Fractional Chief Financial Officer, Chief Financial Officer

Executive Team

Asi Cohen Dotan

Chief Product Officer

Executive Team

Sight Diagnostics Investors

Notable investors and investment history

Sight Diagnostics investors
InvestorRounds
New Alliance CapitalSeries C, Series B
Clal Biotechnology IndustriesSeries C, Series A, Series D
Innovation EndeavorsSeries A
GO CapitalSeries C
Clal IndustriesSeries D
Clal Insurance Enterprises Holdings Ltd.Series D
Longliv VenturesSeries C, Series D

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 19, 2026

    Monthly visitors grew 382% MoM, reaching 2.6K.

  • Apr 21, 2026

    Entire workforce of approximately 20 employees laid off.

Sight Diagnostics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Sight Diagnostics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Sight Diagnostics's valuation, stock price, and market status.

Firmographic Details

HeadquartersTel Aviv
Employee Range65
Year Founded2011
Last FundingAug 5, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.